NASH is a progressive liver disease which is estimated to affect over 5% of the US adult population.2

NASH is characterized by a buildup of fat in the liver, which becomes inflamed, leading to the development of fibrosis. Once the disease progresses to significant (F2) or advanced (F3) fibrosis, the risk of liver related adverse events such as cirrhosis, liver decompensation, the need for liver transplant and ultimately death increases significantly. In addition, patients with NASH are at increased risk for developing cardiovascular disease such as heart attacks and strokes.

We are currently conducting a late-stage clinical program with saroglitazar to assess efficacy and safety in patients with NASH and significant or advanced liver fibrosis.

REFERENCES: 1. Primary biliary cholangitis (2020) NORD (National Organization for Rare Disorders). Available at: (Accessed: November 29, 2022). 2. Lazarus JZ, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78.